Pharmatech launches new contracting services subsidiary in Qatar

laboratory
The new operation will offer single-source platforms for clients and investors. (Pixabay)

Pharmatech Associates, a California-based consulting firm, has launched a new subsidiary headquartered in Doha, Qatar, that will offer global pharmaceutical companies a wide range of consulting services. 

The new operation will offer single-source platforms for clients and investors to help produce next-generation pharmaceutical facilities that can be designed, constructed and operated globally, the company said.

The new subsidiary has been dubbed Pharmatech Associates International Contracting and Services (PAICS).

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Neither the high costs of construction nor lack of local manufacturing expertise should prohibit opportunities for growth and expansion,” Bikash Chatterjee, Pharmatech’s president and chief science officer, said in a statement. “We are extending the Pharmatech brand … to create new, local facilities that integrate product and process development, compliance, regulatory affairs and validation from drug design to commercialization.”

Earlier this year, Pharmatech expanded its executive management team with the promotion of Michaela Mueller as its CFO and corporate secretary. Prior to that, Mueller served as CFO and VP of human resources. 

Read more on

Suggested Articles

WIRB-Copernicus Group has added two new executives to its roster as it expands its Global Research Network of investigative sites.

Incoming FDA Commissioner Ned Sharpless used his first official talk to ensure we all know he’s not looking to tear up Scott Gottlieb’s legacy.

Charles River Labs and the CHDI Foundation have signed a five-year extension for their Huntington’s disease work.